[New therapy concepts for heart failure with preserved ejection fraction].

Herz
C Tschöpe, Burkert Pieske

Abstract

The management of patients with heart failure and preserved ejection fraction (HFpEF) remains challenging and requires an accurate diagnosis. Although currently no convincing therapy that can prolong survival in patients with HFpEF has been established, treatment of fluid retention, heart rate and control of comorbidities are important cornerstones to improve the quality of life and symptoms. In recent years many new therapy targets have been tested for development of successful interventional strategies for HFpEF. Insights into new mechanisms of HFpEF have shown that heart failure is associated with dysregulation of the nitric oxide-cyclic guanosine monophosphate-protein kinase (NO-cGMP-PK) pathway. Two new drugs are currently under investigation to test whether this pathway can be significantly improved by either the neprilysin inhibitor LCZ 696 due to an increase in natriuretic peptides or by the soluble guanylate cyclase stimulator vericiguat, which is also able to increase cGMP. In addition, several preclinical or early phase studies which are currently investigating new mechanisms for matrix, intracellular calcium and energy regulation including the role of microRNAs and new devices are presented and discussed.

References

Mar 31, 1998·Diabetes·D J Drucker
Jul 11, 2000·Journal of Molecular and Cellular Cardiology·P Lijnen, V Petrov
Jan 15, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Patrice ColinAlain Berdeaux
Sep 18, 2002·Journal of Molecular and Cellular Cardiology·Gerd Hasenfuss, Burkert Pieske
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Jul 18, 2003·The American Journal of Medicine·Arnfried U KlingbeilRoland E Schmieder
Mar 28, 2006·The Journal of Pharmacology and Experimental Therapeutics·Yejia SongLuiz Belardinelli
Jul 21, 2006·The New England Journal of Medicine·Theophilus E OwanMargaret M Redfield
Jul 21, 2006·The New England Journal of Medicine·R Sacha BhatiaPeter P Liu
Sep 12, 2006·European Heart Journal·John G F ClelandUNKNOWN PEP-CHF Investigators
Jul 25, 2007·Circulation·Houman AshrafianLionel H Opie
Nov 21, 2007·European Journal of Heart Failure·Jasper W L HartogDirk J van Veldhuisen
Jan 30, 2008·Circulation·Silvio E Inzucchi, Darren K McGuire
Apr 2, 2008·The New England Journal of Medicine·Nigel S BeckettUNKNOWN HYVET Study Group
Apr 17, 2008·Circulation·Dirk WestermannCarsten Tschöpe
Nov 13, 2008·The New England Journal of Medicine·Barry M MassieUNKNOWN I-PRESERVE Investigators
Mar 4, 2009·Basic Research in Cardiology·Dirk WestermannCarsten Tschöpe
Nov 19, 2009·The New England Journal of Medicine·Stefan D AnkerUNKNOWN FAIR-HF Trial Investigators
Feb 4, 2010·Circulation·Anne-Marie LompréAndrew R Marks
Aug 6, 2010·European Journal of Heart Failure·Carolyn S P LamRamachandran S Vasan
Sep 4, 2010·Journal of the American College of Cardiology·Barry A BorlaugMargaret M Redfield
Dec 25, 2010·Basic Research in Cardiology·Kisho Ohtani, Stefanie Dimmeler

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.